Cuorips Inc.
4894 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 中央区日本橋本町三丁目１１番５号 日本橋ライフサイエンスビルディング２、５０７
- Website:
- https://cuorips.co.jp/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cuorips Inc. is a pioneering Japanese biotechnology company dedicated to advancing medicine and healthcare. By focusing on the research, development, and manufacturing of innovative cell products, Cuorips aims to enhance the quality of life and safeguard "life" and "smiles." Notably, the company has achieved a significant milestone by creating the world's first cardiomyocyte sheet derived from induced pluripotent stem (iPS) cells. This groundbreaking development underscores Cuorips' commitment to transforming medical care and addressing critical health challenges. With a strong emphasis on scientific innovation and ethical practices, Cuorips Inc. continues to lead the way in cellular technology and regenerative medicine.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-25 08:39 |
Inside Information Statement
臨時報告書
|
Japanese | 22.9 KB | |
| 2025-06-20 08:39 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2025-06-20 08:38 |
Internal Control over Financial Reporting
内部統制報告書－第9期(2024/04/01－2025/03/31)
|
Japanese | 21.5 KB | |
| 2025-06-20 08:37 |
Annual Report
有価証券報告書－第9期(2024/04/01－2025/03/31)
|
Japanese | 2.3 MB | |
| 2024-11-14 02:30 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-11-14 02:24 |
Interim Report
半期報告書－第9期(2024/04/01－2025/03/31)
|
Japanese | 162.2 KB | |
| 2024-07-01 02:38 |
Inside Information Statement
臨時報告書
|
Japanese | 22.2 KB | |
| 2024-06-27 09:38 |
Internal Control over Financial Reporting
内部統制報告書－第8期(2023/04/01－2024/03/31)
|
Japanese | 21.2 KB | |
| 2024-06-27 09:37 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-06-27 09:36 |
Annual Report
有価証券報告書－第8期(2023/04/01－2024/03/31)
|
Japanese | 2.9 MB | |
| 2024-02-13 07:36 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-02-13 07:36 |
Quarterly Report
四半期報告書－第8期第3四半期(2023/10/01－2023/12/31)
|
Japanese | 132.3 KB | |
| 2023-11-10 08:29 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2023-11-10 08:23 |
Quarterly Report
四半期報告書－第8期第2四半期(2023/07/01－2023/09/30)
|
Japanese | 153.3 KB | |
| 2023-08-10 09:08 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |